Breaking
Vanda Pharmaceuticals Launches NEREUS (Tradipitant) - First New Motion Sickness Drug in 40+ Years Now AvailableTakeda's TAK-881 Meets Primary Endpoint in Phase 2/3 Trial for Primary Immunodeficiency DiseaseFDA Approves LANGLARA Interchangeable Biosimilar to Lantus Insulin - Lannett Company Receives Key Diabetes Drug Approval
🇪🇺 EMA

Vaccine Technology

Page 1 • 1 item

Unlock global vaccine technology insights for pharma BD, investment, and R&D. Stay ahead in infectious disease and therapeutic innovation.